Contacting the SEC will only create more headaches and perhaps cause delays in the current processes the company is trying to complete.
They will not intervene; there is no legal justification for it. And if they were to entertain pursuing something against the company (only to later find FOR the company) the money that will be required to pay for legal counsel will be money that can be used toward seeing the treatments come to fruition.
Now, do we really want to create more issue with the state of the PPS by attempting to have the SEC scrutinize BMSN? I think not.
If you are opposed to the increase to pay for the science and all the fees associated with BMSN securing the rights, how do you propose the company pays for it? Please, spell it out for us with specifics.
BMSN
News 
Market Data 
Discover 
AI
